Group items tagged

"Mesenchymal Stem Cells - Advances And Applications"are multipotent stem cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, and potentially, neuronal cells.

Human embryonic stem cells were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison.

"World Medical Device Packaging". World medical device packaging product demand will increase 5.9 percent yearly to $25.7 billion in 2017.

The 3D cell culture market is driven by increased investment in healthcare, R&D, and other research-related activities. The novel concept of customized 3D cell culture products has allowed small companies to enter the market. Large-sized companies have focused on product launch to cater to the specific requirements of the researchers. For instance, Thermo Fisher Scientific collaborated with Applikon Biotechnology and launched two new single-use bioreactor controller platforms-i-Control and ez-Control.

Platelet-rich plasma is a coagulated blood-rich polymer, made from extracted platelets. Extracted platelets are normally coagulated by monocytes or lymphocytes with fibrin. Platelets are also commonly injected into the body's bloodstream to support tissue healing following tissue surgery. Platelet-rich plasma has been found effective against bleeding disorders. It also helps reduce the risk of deep vein thrombosis (DVT) in patients with high blood pressure and in those taking anticoagulants. It may also reduce the risk of pulmonary embolism (PE), which is blood clots that enter the lungs and pulmonary system. In the chest, the clot can stop or limit the flow of blood to the heart. PE often leads to cardiac arrest and death. Increasing cosmetic surgeries is expected to drive growth of the global platelet rich plasma market during the forecast period. Cosmetic surgeries refer to surgical specialty involving the restoration, alteration, or reconstruction of the human body. According to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2018, around 128,398 cosmetic procedures in Thailand and 1,036,618 procedures in Mexico were carried out. Hence, these factors are expected to drive growth of the global platelet rich plasma market during the forecast period. Furthermore, increasing prevalence of cosmetic surgeries is expected to boost the global platelet rich plasma market growth over the forecast period. Read more @ https://sachinbhombe.blogspot.com/2021/03/platelet-rich-plasma-market-is-witness.html

To bring new therapies to market, pharmaceutical, biotechnology, and medical device companies engage contract research organizations (CROs).